We saw similar levels of tumor suppression in another independent study with HCT116 IDH1-mutant xenograft model, with smaller sample size (n = 5), where the combination therapy at lower dose of AZD6738 (25 mg/kg) and olaparib (25 mg/kg) was also effective in causing a significant tumor growth delay (Figure 6D and Supplementary Figure S8). Here, IDH1 is linked to neoplasm.